Regulatory · Documentation

What is a certificate of a pharmaceutical product (CPP)?

By LNJC· · 6 min read

A certificate of a pharmaceutical product (CPP) is the primary document of the WHO Certification Scheme. A participating certifying authority issues it on application, attesting whether a product is authorised on its market, that the manufacturing site is inspected for GMP compliance, and that the product information, including labelling, is currently authorised.

WHA22.50the resolution in which the Scheme was initially recommended (WHO TRS 1033, Annex 9, 3.3)
2 situationsin which the requesting authority is intended to use a CPP (section 5.5)
Confidentialissued only with the permission of the applicant or marketing authorization holder (5.8)

What is the WHO Certification Scheme?

It is a voluntary agreement between participating countries about the quality of medicines that cross borders. WHO Technical Report Series No. 1033, Annex 9, Guidelines on the implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, published in the Fifty-fifth report (2021), describes the Scheme as "an international voluntary agreement to provide assurance to countries participating in the Scheme about the quality of pharmaceutical products moving in international commerce".1

The same guideline names the certificate of a pharmaceutical product as the primary document of the Scheme, and says the Scheme was recommended initially in resolution WHA22.50. It calls the Scheme an administrative instrument: each participating Member State or regional authority, upon application by a commercially interested party, attests certain facts about a product to the competent authority of another participating Member State or regional authority.1

What does a CPP attest?

It attests the regulatory standing of a product in the certifying jurisdiction. Section 3.3 of Annex 9 lists, among the points the certifying authority attests, that:1

The first item cuts both ways. A certificate can also record that a product is not authorised in the certifying jurisdiction, together with the reason. A manufacturer should know in advance what its own certificate will say on that line.

Who issues a CPP, and who receives it?

The certifying authority issues it, and the requesting authority in the importing country receives it. Annex 9 says the certificate is a confidential document that the certifying authority may issue only with the permission of the applicant or of the marketing authorization holder.1

Section 5.9 says the certificate is intended to be incorporated into a marketing authorization application to the requesting authority. Once prepared, it is transmitted to the requesting authority through the applicant and, when applicable, the agent in the importing country.1 That is one reason the choice of local partner matters early; see the authorised importer and the local agent.

When is a CPP used?

At the start of a marketing authorization and when that authorization changes. Section 5.5 of Annex 9 says the CPP is intended for use by the requesting authority in two situations:1

Section 5.6 adds that the CPP is intended to facilitate the trade of pharmaceutical products, that its use should affect the quality and time of dossier assessment for regulatory authorities and regional bodies, and that the Scheme facilitates reliance among participating authorities and enables timely access to medicines.1 In practice, a manufacturer that plans a market several years out should also plan for the certificate being needed again when the authorization is renewed or varied.

What is a CPP not?

It is not a standalone guarantee of safety or efficacy, and it is not a channel for further information. The Scheme frames the certificate as an attestation about marketing authorization status, GMP inspection of the site, commercialisation and authorised product information. The requesting authority still makes its own assessment of the application the certificate sits inside.1

Section 5.13 is direct on the second point: additional information is not within the scope of the Scheme, and the certifying authority is under no obligation to supply it.1

Nor is every certificate that mentions the Scheme a CPP. Annex 9 lists examples of statements and certificates issued in connection with the Scheme that are not considered part of it. One is the statement of marketing authorization status of pharmaceutical products, which, in the guideline's words, "attests only that a marketing authorization has been issued for a specified product, or products, for use in the certifying country or within the jurisdiction of the certifying regional authority".1 It does not carry the GMP inspection and product information attestations of a CPP, so the two should not be treated as interchangeable.

How does this apply to products for the Republic of Yemen?

Start from the international framework above: know what your certifying authority will attest, who must give permission for issue, and how the certificate will travel through the applicant and any agent in the importing country. Which documents the national authority in the Republic of Yemen currently asks for, and in what form, is confirmed case by case for the specific product, and is worth raising before a dossier is assembled.

LNJC handles the documentation manufacturers provide as part of its import process. For the wider picture of the market, see entering the Yemen market, and for the border side, how medical products are cleared for import.

Frequently asked questions

What is a certificate of a pharmaceutical product (CPP)?

It is the primary document of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. A participating certifying authority issues it on application, attesting to another participating authority whether a product is authorised on its market, that the manufacturing site is inspected for GMP, and that the product information is currently authorised.

Who can ask for a CPP to be issued?

According to WHO Technical Report Series No. 1033, Annex 9, the certifying authority acts upon application by a commercially interested party. The certificate is confidential and may be issued only with the permission of the applicant or of the marketing authorization holder. It then reaches the requesting authority through the applicant and, when applicable, the agent in the importing country.

Is a statement of marketing authorization status the same as a CPP?

No. WHO Technical Report Series No. 1033, Annex 9, lists the statement of marketing authorization status as an example of a document issued in connection with the Scheme but not part of it. It attests only that a marketing authorization has been issued for a specified product for use in the certifying country or region.

Does a CPP prove that a medicine is safe and effective?

Not on its own. The Scheme frames the certificate as an attestation by the certifying authority about marketing authorization status, inspection of the manufacturing site for GMP compliance, commercialisation status and authorised product information. The requesting authority uses it as part of its own assessment of a marketing authorization application.

References

  1. World Health Organization, Guidelines on the implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, WHO Technical Report Series No. 1033, Annex 9, Fifty-fifth report (2021), sections 1, 3 and 5. Accessed 15 October 2026. cdn.who.int